Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of “Hold” by Brokerages

Seres Therapeutics, Inc. (NASDAQ:MCRB) has earned a consensus rating of “Hold” from the five analysts that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $4.00.

Several equities analysts have commented on the stock. The Goldman Sachs Group cut their target price on shares of Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating on the stock in a research note on Friday. StockNews.com upgraded shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 6th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $10.00 target price on shares of Seres Therapeutics in a research note on Thursday, November 14th.

Seres Therapeutics Price Performance

MCRB traded up $0.05 during trading hours on Friday, reaching $0.69. The company’s stock had a trading volume of 807,342 shares, compared to its average volume of 1,392,801. The stock has a market cap of $120.10 million, a PE ratio of -3.00 and a beta of 2.19. The business’s 50-day moving average is $0.80 and its 200-day moving average is $0.83. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $1.53.

Hedge Funds Weigh In On Seres Therapeutics

Institutional investors have recently modified their holdings of the company. Avantax Advisory Services Inc. increased its position in Seres Therapeutics by 170.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 28,500 shares during the last quarter. Jane Street Group LLC grew its position in shares of Seres Therapeutics by 181.4% during the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company’s stock worth $49,000 after buying an additional 37,866 shares in the last quarter. Virtu Financial LLC raised its stake in Seres Therapeutics by 44.8% during the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 18,191 shares in the last quarter. Providence Wealth Advisors LLC grew its position in shares of Seres Therapeutics by 29.2% during the 3rd quarter. Providence Wealth Advisors LLC now owns 98,500 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 22,250 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Seres Therapeutics by 20.4% in the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company’s stock valued at $218,000 after buying an additional 44,461 shares during the last quarter. Institutional investors and hedge funds own 59.34% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.